Clinical Trial: A Phase III Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07309055) titled 'A Phase III Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis' on Dec. 15.

Brief Summary: This trial was designed to evaluate the efficacy and safety of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Adolescents With Moderate-to-severe Atopic Dermatitis

Intervention: DRUG: SHR-1819 Injection

SHR-1819 injection.

DRUG: SHR-1819 Injection Placebo

SHR-1819 injection placebo.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

Published by HT Digital Content Services with permissi...